Heron Therapeutics, Inc. (HRTX) stock
Close on Nov 11, 2026Market cap $68.21MP/E –Yield –
Heron Therapeutics, Inc. saw revenue fall 4.4% to $148.22M over the twelve months to Sep 30, 2026. Operating income fell 628.5% to -$8.44M, moving the operating margin from 1.0% to -5.7%. Free cash flow was -$14.36M. At the latest close the market valued the company at $68.21M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $68.21M
- P/E ratio
- –
- Price to sales
- 0.46
- Price to book
- 13.88
- Dividend yield
- –
- Free cash flow yield
- -21.05%
Fundamentals
- Revenue
- $148.22M
- Net income
- -$21.56M
- EPS, diluted
- -$0.12
- Free cash flow
- -$14.36M
- Book value per share
- $0.03
- Diluted shares
- 191M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $0.37
- Open
- $0.37
- Day's range
- $0.34 – $0.37
- Volume
- 4,809,742
- Average volume (20 days)
- 9,088,414
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.81
- 52-week range
- $0.26 – $1.57
- RSI (14 days)
- 56.7
- Volatility (1 year)
- 96.1%
- Relative volume
- 1.20×
- WACC
- 13.9%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | HRTX | S&P 500 | Difference | HRTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.5% | -2.4% | −9.1 pts | ||
| 3 months | +11.0% | -1.2% | +12.1 pts | ||
| Year to date | -72.4% | +12.3% | −84.7 pts | ||
| 1 year | -69.0% | +12.4% | −81.5 pts | ||
| 3 years | -38.6% | +78.8% | −117.4 pts | -15.0% | +21.4% |
| 5 years | -96.8% | +75.2% | −172.0 pts | -49.9% | +11.9% |
| 10 years | -98.1% | +311.1% | −409.2 pts | -32.8% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Heron Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- Results
- Results
About Heron Therapeutics
Pharmaceutical Preparations
The company is a commercial-stage biotechnology firm focused on developing and commercializing therapeutic products for acute care and oncology patients. Its acute care product line includes ZYNRELEF, a dual-acting extended-release local anesthetic combining bupivacaine and meloxicam for postoperative pain management, and APONVIE, an intravenous formulation of aprepitant used to prevent postoperative nausea and vomiting. Its oncology offerings consist of CINVANTI and SUSTOL, which are injectable therapies designed to prevent acute and delayed chemotherapy-induced nausea and vomiting. The company markets these treatments in the United States through specialty distributors and full-line wholesalers that supply healthcare providers and hospital systems.
Company profile, executives and historyHeron Therapeutics stock: common questions
What is Heron Therapeutics's stock price?
HRTX closed at $0.36 on Nov 11, 2026, down 3.96% on the day. Over the past 52 weeks it traded between $0.26 and $1.57.
What is Heron Therapeutics's market cap?
Heron Therapeutics was worth $68.21M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is HRTX's P/E ratio?
Heron Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.12), so it has no meaningful P/E ratio.
How much revenue does Heron Therapeutics make?
Heron Therapeutics reported revenue of $148.22M for the twelve months to Sep 30, 2026, down 4.4% from a year earlier.
Does Heron Therapeutics pay a dividend?
No. Heron Therapeutics has not paid a cash dividend over the last twelve months.
When does Heron Therapeutics report earnings next?
Heron Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has HRTX stock performed over the past year?
Including dividends, HRTX returned -69.0% over the past year, against +12.4% for the S&P 500.
How many HRTX shares are sold short?
34M shares were sold short at the latest FINRA report, 22.84% of the float, or 19.5 days of average trading volume.
Who are Heron Therapeutics's competitors?
Companies most similar to Heron Therapeutics by business, industry and size include NUVB, URGN, ETON, AKBA, RCUS.
See a number that looks wrong?